New insights into myelination reviewed through the What, When and Where autism framework

 

A new paper was recently published by researchers at the City University of New York (CUNY) may have implications far beyond myelin disorders such as multiple sclerosis. The study demonstrated that glucose is not merely a fuel source for the developing brain, but also acts as a developmental signal controlling myelin formation.

We know that myelination can be delayed, or just impaired, in many types of autism.

Modern imaging increasingly suggests that some neurodevelopmental disorders involve altered developmental timing of white matter maturation, rather than structural defects.

That fits very well with:

• delayed milestones
• asynchronous development
• regression windows
• partial catch-up trajectories

 

The technology available includes:

Conventional MRI — shows gross white matter and myelination patterns; useful for detecting delayed myelination, hypomyelination, or structural white matter abnormalities.

Diffusion Tensor Imaging (DTI) — advanced MRI technique measuring white matter connectivity and tract integrity indirectly through water diffusion.

Advanced myelin imaging (MTI, Myelin Water Imaging, MRS) — more specialized scans that estimate myelin content or metabolic function related to myelin and brain energy use.

 

Researchers Discover a New Link Between Brain Sugar Levels and Myelin Development

https://www.gc.cuny.edu/news/researchers-discover-new-link-between-brain-sugar-levels-and-myelin-development

 

Oligodendrocytes make myelin, and you need a lot of them.

An oligodendrocyte progenitor cell (OPC) is an immature brain cell that can divide and later mature into an oligodendrocyte, the cell responsible for producing myelin around nerve fibers.

The paper showed that high local glucose levels stimulated oligodendrocyte progenitor cells to divide and increase their numbers rather than mature immediately into myelin-producing cells.

While lower glucose states and alternative fuels such as ketone bodies supported maturation into myelin-producing oligodendrocytes. Importantly, when glucose-derived acetyl-CoA production was impaired, oligodendrocytes were still able to mature and eventually produce myelin by switching to ketone-derived metabolic pathways.

In essence:

·        Glucose was especially important for expanding the number of OPCs.

·        Ketones can support later oligodendrocyte maturation and myelin production when glucose pathways were impaired.

·        Ketones cannot replace glucose

·        Ketones can augment a glucose deficient brain

 

While the study focused on myelination, it may also provide a useful framework for thinking about autism and neurodevelopmental disorders.

One conceptual model I use to understand autism is what I call the “3W framework”, or the What When and Where of autism:

• What dysfunction?
• Where in the brain?
• When during development?

This new research fits remarkably well within this framework.

 

WHAT dysfunction?

Autism is unlikely to represent one single biological abnormality. Two autistic individuals may share behavioral features while having very different underlying neurobiology.

Potential dysfunctions may include:

• Synaptic dysfunction
• Mitochondrial abnormalities
• Redox dysregulation
• Neuroinflammation
• ER stress
• Myelination abnormalities
• Developmental timing abnormalities
• Excitation/inhibition imbalance

This new paper introduces another important candidate dysfunction -
metabolic regulation of oligodendrocyte development and myelination.

The important insight is that metabolism itself appears to regulate developmental state transitions.

The study showed that glucose-derived acetyl-CoA regulates histone acetylation and developmental gene expression in OPCs. In other words, metabolism is not simply supplying energy to the brain. It is helping instruct cells when to proliferate and when to mature.

This is a major conceptual shift.

In autism research, metabolism has traditionally been viewed mainly through the lens of energy deficiency or mitochondrial dysfunction. However, this paper supports a newer idea emerging across neuroscience:

Metabolism may act as a developmental signaling system.

This may help explain why some autistic individuals show:

• Delayed rather than absent development
• Uneven cognitive profiles
• Fluctuating developmental trajectories
• Temporary regressions
• Later partial catch-up

These patterns are difficult to explain using static “brain damage” models but fit more naturally with dysregulated developmental timing.

 

WHERE in the brain?

The same dysfunction can produce very different outcomes depending on where it occurs.

Abnormal myelination in:

• Frontal regions may affect executive function and social cognition
• Temporal regions may affect language processing
• Cerebellar circuits may affect sensory prediction and motor timing
• White matter tracts may affect long-range synchronization and processing speed
• Brainstem regions may affect autonomic regulation and arousal

This may explain why autism presents so heterogeneously.

Importantly, systemic treatments are too blunt. Most interventions affect the entire brain simultaneously. A therapy that improves one network may destabilize another.

This may partly explain why:

• Some individuals improve dramatically with metabolic interventions
• Others show little effect
• Some worsen paradoxically

The “Where” dimension is likely critically important but remains difficult to target clinically.

WHEN during development?

This may be the most important insight of all.

The developing brain is not static. Different developmental stages require different metabolic and signaling environments.

The paper demonstrated that:

• High glucose states supported OPC proliferation
• Alternative metabolic fuels supported oligodendrocyte maturation and myelin synthesis

This implies that metabolic requirements change across developmental stages.

That concept may have profound implications for autism.

Many developmental disorders show:

• Delayed milestones
• Asynchronous development
• Developmental plateaus
• Regression windows
• Later partial catch-up

The traditional assumption has often been that cells or circuits are permanently defective.

However, this paper suggests that some neurodevelopmental disorders may involve delayed or dysregulated developmental transitions rather than irreversible failure.

The study is particularly interesting because the mice initially showed reduced myelination but later partially compensated through alternative metabolic pathways involving ketone-derived acetyl-CoA.

This resembles the developmental trajectories seen in many neurodevelopmental disorders, where:

• Development is delayed rather than absent
• Skills may emerge late
• Periods of apparent stagnation may later resolve
• Regression may sometimes reflect failure of compensation during periods of rising developmental demand

This may help explain why some therapies only appear effective during certain developmental windows.

A treatment beneficial during one phase of development may be ineffective or even counterproductive during another.

 

Implications for autism therapies

This paper does not prove that autism is a myelination disorder, nor does it prove that ketogenic therapies are effective for autism.

However, it strengthens several emerging ideas:

• Metabolism may regulate developmental timing
• Myelination may be metabolically sensitive
• Alternative fuels such as ketones may support some developmental processes
• Neurodevelopmental disorders may involve impaired metabolic flexibility
• Therapeutic timing may matter enormously

The future of autism therapy may eventually require understanding:

• What dysfunction is present
• Where it is occurring in the brain
• When during development intervention is most effective

The era of searching for a single universal autism treatment may eventually give way to developmentally timed, biologically targeted interventions tailored to specific neurobiological profiles.

This new myelination research may represent an important step toward that future.

Note that this paper from CUNY does not mention autism, it is just about the myelination process.

 

The use of ketones in autism

A small number of people with autism appear to respond very well to ketone ester supplements. These products are still relatively niche, expensive, and can be difficult to obtain outside the United States. One of the best known examples is KetoneAid KE4.

Ketone esters can produce a substantial and measurable increase in blood levels of the ketone beta-hydroxybutyrate (BHB), often sustained for several hours. This differs significantly from many cheaper “ketone” products, particularly ketone salts, which typically produce much smaller and shorter-lived increases in BHB.

Why some autistic individuals respond positively to ketones remains unclear, but several mechanisms are plausible:

• Alternative brain energy supply
• Improved mitochondrial efficiency
• Reduced glucose dependence
• Changes in redox balance
• Effects on neuronal excitability
• Altered inflammation and signaling pathways
• Possible support for myelination and oligodendrocyte function

The new study showed that oligodendrocyte lineage cells can switch from glucose-derived acetyl-CoA to ketone-derived acetyl-CoA during later stages of myelin formation. This suggests ketones may play a more important developmental and signaling role in the brain than previously appreciated.

Importantly, ketones do not replace glucose entirely. The study demonstrated that glucose signaling remained necessary for oligodendrocyte progenitor cell (OPC) proliferation during early developmental stages, while ketones could support later maturation and myelin synthesis under some conditions.

This may help explain why ketones appear beneficial in some neurological and developmental conditions involving:

• impaired glucose utilization
• mitochondrial dysfunction
• epilepsy
• white matter abnormalities
• metabolic inflexibility

However, responses in autism are highly variable. Some individuals show improvements in:

• alertness
• cognition
• endurance
• behavior
• seizures
• language attempts

while others show little benefit or even worsening.

This variability likely reflects the biological heterogeneity of autism itself. Different individuals may have different underlying dysfunctions involving metabolism, redox balance, mitochondrial function, neuroinflammation, myelination, or neuronal signaling.

At present there is still very little formal clinical research on ketone esters in autism, and most evidence remains anecdotal or exploratory. Nevertheless, the growing understanding of brain metabolism and developmental myelination suggests this may become an increasingly important research area in the future.